QBie™ Spotlight: Kane Biotech Inc. (OTCQB: KNBIF)
What does Kane Biotech do?
Mark Ahrens-Townsend (President & CEO- OTCQB: KNBIF): “Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. Biofilms are formed when bacteria and/or fungi adhere to surfaces and excrete a glue-like substance that acts as an anchor and provides protection from the environment. Biofilm formation can make bacteria up to 1000 times more resistant to antibiotics, antimicrobial agents, disinfectants and the host immune system and are acknowledged to be one of the main contributors to the “antibiotic resistance crisis”. Consequently, biofilm related infections are difficult to treat and they commonly manifest themselves as chronic or recurrent in nature. Biofilms can form on both living and non- living surfaces including teeth (plaque and tartar), skin (wounds and diseases like seborrheic dermatitis), medical devices (catheters and endoscopes), kitchen sinks and counter tops, food and food processing equipment, hospital surfaces, pipes and filters in water treatment plants, and oil, gas and petrochemical process control facilities. As a result, significant antibiofilm opportunities for Kane Biotech exist in animal health and human health, as well as several large commercial, institutional and industrial applications.
Kane Biotech owns a rich portfolio of intellectual property including 75 patents and patents pending plus trademarks, trade secrets and products developed by the Company’s own biofilm research experts and acquired from leading research institutions. Kane Biotech has developed highly effective and safe commercial product brands being sold today in the companion pet market. However, our mission is to be a royalty based revenue company licensing our technologies to global industry players, first for applications in the companion pet animal health market followed by the human health market. The Company’s 1st multi-year, multi-million dollar licensing agreement was signed in 2017 with Dechra Veterinary Products LLC for the North American veterinary market. The agreement includes Kane Biotech’s StrixNB™ companion pet oral care and DispersinB® dermatology products based on two of the Company’s patented and patent pending technologies.”
What is the next big goal Kane Biotech is trying to accomplish/what should we keep an eye out for?
Mark Ahrens-Townsend: “Kane Biotech has significant additional opportunities for licensing our oral care and dermatology technologies and increasing our royalty and milestone payments in the companion pet market during 2018. In addition to launching new products in the veterinary market with Dechra, Kane is focused on licensing and distribution agreements in the North American pet specialty market as well as expanding our companion pet technologies into international markets. On the human health side the Company is finalizing formulations based on our patented technologies for the treatment of chronic inflammatory skin disorders such as athlete’s foot, eczema and seborrheic dermatitis. The testimonial results of our technology on these conditions has been very strong. The Company plans to conduct clinical trials on these conditions commencing in 2018 and in parallel seek large market access partners for the commercialization of products based on our technology.”
Why did you join the OTCQB?
Mark Ahrens-Townsend: “Kane Biotech is publicly traded on the TSX Venture exchange (Symbol: “KNE”) which caters primarily to investors in the Canadian stock market. We believe U.S. based investors will be interested in Kane Biotech which has built a world-class portfolio of intellectual property in the widely-applicable biofilm dispersion and prevention space, and we are actively negotiating commercial partnerships to license our technology in various industries and applications. Being on the OTCQB® Venture Market (Symbol: “KNBIF”) opens access to tiers of investors, whom were previously untapped, that are enthusiastic about our story and support our development. In addition, the public markets allow us to access capital easier, execute on our international growth strategies and be more visible and better recognized by potential commercial partners.”
How can members of the microcap community help you?
Mark Ahrens-Townsend: “Commencing in 2018 the Company is undertaking an active investor relations campaign to communicate the Kane Biotech opportunity. We encourage current shareholders and potential investors to learn about the many problems and opportunities associated with biofilms and how Kane Biotech’s technologies are positioned to have significant impact on these. At our current market valuation Kane Biotech shares offer considerable upside to investors who want to buy in now. In addition, the microcap community is ripe with development-stage companies that are utilizing their technology in innovative ways. Being in the same arena facilitates easier introduction of Kane Biotech to potential partners ranging from animal and human health focused companies to industrial equipment manufacturers so they can realize how Kane’s biofilm inhibition and dispersion technologies may optimize the safety and development of their own products and technologies. Potential royalty-based agreements further build Kane Biotech’s visibility among increasingly-larger circles which is leading to Kane Biotech’s success in securing commercial partnerships with internationally-recognized corporations.”
QBie™ Spotlight is a virtual “welcome interview” for new OTCQB companies. QBie™ Spotlight helps issuers that are new to the OTCQB connect with microcap industry professionals! Learn more about the QBie™ Spotlight HERE.
Disclaimer/Forward Looking Statements:
This Website and its contents are not to be construed, under any circumstances, as an offer to sell or a solicitation to buy or effect transactions in any securities. No investment advice is provided or should be construed to be provided herein. This Website and its owners, employees and affiliates are not, nor do any of them claim to be, registered broker-dealers or registered investment advisors. This Website may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws, including, but not limited to, any projections of earnings, revenue or other financial items; any statements of the plans, strategies and objectives of management for future operations; any statements concerning proposed new services or developments; any statements regarding future economic conditions or performance; any statements of belief; and any statements of assumptions underlying any of the foregoing. Such forward-looking statements of or concerning the companies mentioned herein are subject to numerous uncertainties and risk factors, including uncertainties and risk factors that may not be set forth herein, which could cause actual results to differ materially from those stated herein. Accordingly, user of this Website are cautioned not to place undue reliance on such forward-looking statements. This Website undertakes no obligation to update any forward-looking statements that may be contained herein.